Integrative CBT for Prolonged Grief Beats Present-Centered Therapy
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 27, 2024 -- For patients with prolonged grief disorder (PGD), integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT) after treatment, according to a study published online Nov. 13 in JAMA Psychiatry to coincide with the European Grief Conference, held from Nov. 11 to 13 in Dublin.
Rita Rosner, Ph.D., from the Catholic University Eichstätt-Ingolstadt in Germany, and colleagues examined whether PG-CBT is superior to PCT in a rater-blinded, multicenter, randomized clinical trial. Participants were aged 18 to 75 years and had PGD; they were randomly assigned to receive PG-CBT and PCT in a 1:1 ratio (106 to each condition).
The researchers found that at follow-up, both treatments yielded high reductions in PGD severity in the intention-to-treat analysis (Cohen d = 1.64 and 1.38 for PG-CBT and PCT, respectively). After treatment, significantly greater reductions in PGD severity were seen for those receiving PG-CBT versus PCT (Cohen d = 0.31). This effect was only visible on a trend level at follow-up 12 months after randomization; however, significantly less depressive and psychopathological symptoms were seen for participants in the PG-CBT group. Twenty and 16 percent of participants discontinued PG-CBT and PCT, respectively.
"PG-CBT was an efficient treatment and has great potential for widespread dissemination," the authors write. "PCT could be of interest to patients who do not wish to focus on the loss and could thus contribute to increasing patient choice."
Several authors disclosed ties to the pharmaceutical and publishing industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-28 06:00
Read more
- New Alzheimer's prevention trial receives $74.5 million NIH grant
- Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
- Once Again, Tuberculosis Becomes World's Top Infectious Disease Killer
- Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease
- Flu-Linked Hospitalization Rates Vary Across Seasons, Highest in Adults 65+
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions